PSMD5

Across TCGA pan-cancer cohorts, PSMD5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PSMD5 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PSMD5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PSMD5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and ACC are the cancer types where PSMD5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.250	0.678	.003	12	view →
UCEC	DFS	Median	All	0.961	0.624	.013	10	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PSMD5–LUSC (OS)

Open the LUSC breakdown →